肝硬化患者接受不同肝细胞癌筛查检测的比例与预测因素
结果显示46%的患者接受了筛查,筛查率和模式因设施而异,筛查与种族/民族、BMI≥25、肝硬化病因、血小板减少、Fibrosis-4≥3.25及较低的MELD-Na评分相关。
要点
- 近半数肝硬化患者在6个月内接受了肝细胞癌筛查。
- 筛查率和筛查模式(超声、CT、MRI、AFP)因医疗设施而异。
- 高风险患者更可能接受筛查。
核心结论
- 肝硬化患者肝细胞癌筛查率因设施而异,高风险患者更可能接受筛查。
主要发现
- 46%的患者在6个月内接受了肝细胞癌筛查。
- 筛查率和筛查模式(超声、计算机断层扫描、磁共振成像、血清甲胎蛋白)因设施而异。
- 筛查与种族/民族、体重指数≥25、肝硬化病因、血小板减少、Fibrosis-4≥3.25及较低的MELD-Na评分相关。
临床怎么用
- 临床中应关注肝硬化患者的肝细胞癌筛查,尤其是高风险患者,并注意不同设施间筛查率的差异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: We aimed to assess rates and predictors of hepatocellular carcinoma (HCC) screening among patients with cirrhosis. METHODS: We reviewed electronic health records of 11,361 patients with cirrhosis from 11 U.S. Veterans Health Administration facilities for receipt of HCC screening in the 6 months preceding October 1, 2019. RESULTS: Nearly half of the cohort (46%) received HCC screening over a 6-month period. Screening rates and modalities (ultrasound, computed tomography, magnetic resonance imaging, serum alpha fetoprotein) varied by facility. Screening was associated with race/ethnicity, body mass index ≥ 25, cirrhosis etiology, thrombocytopenia, Fibrosis-4 ≥ 3.25, and lower Model for End-Stage Liver Disease-Sodium. DISCUSSION: HCC screening rates varied by facility. Higher risk patients were more likely to receive screening.
引用
- Kim NJ, Jacob DA, Ioannou GN, et al. Rates and Predictors of Undergoing Different Hepatocellular Carcinoma Screening Tests in Patients With Cirrhosis. Am J Gastroenterol. 2021. PMID: 33252455. doi:10.14309/ajg.0000000000001000
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。